Primary Amine Compounds Sequester All-Trans-Retinal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Age-related macular degeneration and other ocular disorders are exacerbated by aberrant metabolism of all-trans-retinal, leading to toxic compounds that impair photoreceptor function and vision, with existing treatments either ineffective or causing undesirable side effects.
Innovation Solution
Development of compounds incorporating deuterium and fluorine to modulate the visual cycle, specifically primary amines that sequester all-trans-retinal in ocular tissue, inhibiting RPE65 enzymatic activity while maintaining normal retinoid cycle performance and avoiding night blindness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If RPE65 is completely suppressed to reduce all-trans-retinal toxicity, then toxic compound formation is reduced, but vision is completely impaired
Solution Approach 1:
The patent applies partial suppression of RPE65 activity rather than complete inhibition. The compounds reduce all-trans-retinal toxicity through adduction while maintaining attenuated RPE65 activity, achieving therapeutic effect without complete functional loss. This partial action resolves the contradiction by providing sufficient toxicity reduction while preserving minimal visual function.
Solution Approach 2:
The patent introduces primary amine compounds as intermediary agents that mediate between RPE65 inhibition and visual function preservation. These compounds act as dual-function agents: they inhibit RPE65 to reduce toxic retinal formation while simultaneously serving as sinks to sequester excess all-trans-retinal, thereby protecting photoreceptors and maintaining vision.
2Object-affected harmful factors
If RPE65 is inhibited to slow all-trans-retinal generation, then toxic metabolism is reduced, but chromophore regeneration is impaired
Solution Approach 1:
The primary amine compounds serve as intermediary agents that compensate for the slowed chromophore regeneration. By acting as alternative sinks for all-trans-retinal, they prevent the accumulation of toxic metabolites that would otherwise result from inhibited RPE65 activity, thus maintaining overall retinal homeostasis despite reduced regeneration rate.
Solution Approach 2:
The patent extracts excess all-trans-retinal from the visual cycle through adduction to primary amine compounds. This removal of excess retinal prevents its conversion to toxic compounds while the inhibited RPE65 continues to function at reduced capacity, balancing toxicity reduction with adequate chromophore availability.
3Object-affected harmful factors
If existing treatments are used to address all-trans-retinal toxicity, then some therapeutic effect is achieved, but undesirable side effects occur
Solution Approach 1:
The patent converts the potential harm of all-trans-retinal accumulation into a beneficial therapeutic mechanism. The primary amine compounds exploit the natural production of all-trans-retinal by RPE65, using it as a substrate for adduction reactions that actively remove toxic retinal from the system. The very metabolic pathway that produces toxicity is harnessed to drive the therapeutic sequestration process.
Solution Approach 2:
The primary amine compounds perform multiple functions simultaneously: they inhibit RPE65 enzymatic activity, sequester excess all-trans-retinal through adduction, and prevent the formation of toxic compounds. This multi-functionality achieves comprehensive toxicity reduction without requiring multiple separate treatments, thereby minimizing side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reduce the toxicity of all-trans-retinal, mitigating retinal degeneration and maintaining normal visual cycle function, thereby treating age-related blindness without causing night blindness.
Implementation Method 1
Regioselective incorporation of deuterium can be used to attenuate amine oxidation and rapid metabolic elimination via engineering a localized primary isotope effect
Implementation Method 2
Regioselective incorporation of fluorine can impact pKa modulation; alter target selectivity through conformational variations or changes in specific hydrophobic interactions
Implementation Method 3
alter target selectivity through conformational variations or changes in specific hydrophobic interactions
Implementation Method 4
alter tissue-specific penetration (e.g., central nervous system (CNS)), through modification of lipophilicity
Implementation Method 5
The compound upon administration to a subject transiently sequesters all-trans-retinal in ocular tissue of the subject by forming a reversible Schiff-base with the all-trans-retinal
Implementation Method 6
Regeneration of the visual chromophore following light exposure is dependent upon an enzymatic pathway referred to as the visual cycle
Data Source
AI summary
A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof.